Company news
Intellia Therapeutics, Inc. news in 2023
Intellia Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
November 13, 2023
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 8, 2023
Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting
November 1, 2023
Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November
October 25, 2023
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
October 17, 2023
Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
October 12, 2023
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
October 2, 2023
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 2, 2023
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates
July 26, 2023
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)
June 10, 2023
Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors
June 4, 2023
Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023
May 30, 2023
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 3, 2023
Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities
April 30, 2023
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates
April 26, 2023
Intellia Therapeutics Names Bill Chase to its Board of Directors
April 16, 2023
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema
March 20, 2023
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)
March 1, 2023
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
February 22, 2023
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates
February 15, 2023
Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
January 10, 2023
Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones
January 4, 2023
Calls in 2023
- Intellia Therapeutics (NASDAQ:NTLA) Q3 2023 Earnings Call
Nov 9, 2023
Transcript - Intellia Therapeutics (NASDAQ:NTLA) Q2 2023 Earnings Call
Aug 3, 2023
Transcript - Intellia Therapeutics (NASDAQ:NTLA) Q1 2023 Earnings Call
May 4, 2023
Transcript - Intellia Therapeutics (NASDAQ:NTLA) Q4 2022 Earnings Call
Feb 23, 2023
Transcript
Decks in 2023
- International Symposium on Amyloidosis (ISA) Meeting, Madrid, November 2-3, 2023
Conference · 16 slides · Nov 2, 2023
- Technical Presentation (June 2023)
Technical · 32 slides · Jun 12, 2023